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Abstract: Rett syndrome (RTT) is a neurodevelopmental disorder, affecting 1 in 10,000 girls. Intellectual
disability, loss of speech and hand skills with stereotypies, seizures and ataxia are recurrent features.
Stringent diagnostic criteria distinguish classical Rett, caused by a MECP2 pathogenic variant
in 95% of cases, from atypical girls, 40–73% carrying MECP2 variants, and rarely CDKL5 and
FOXG1 alterations. A large fraction of atypical and RTT-like patients remain without genetic cause.
Next Generation Sequencing (NGS) targeted to multigene panels/Whole Exome Sequencing (WES)
in 137 girls suspected for RTT led to the identification of a de novo variant in STXBP1 gene in four
atypical RTT and two RTT-like girls. De novo pathogenic variants—one in GABRB2 and, for first
time, one in GABRG2—were disclosed in classic and atypical RTT patients. Interestingly, the GABRG2
variant occurred at low rate percentage in blood and buccal swabs, reinforcing the relevance of
mosaicism in neurological disorders. We confirm the role of STXBP1 in atypical RTT/RTT-like patients
if early psychomotor delay and epilepsy before 2 years of age are observed, indicating its inclusion
in the RTT diagnostic panel. Lastly, we report pathogenic variants in Gamma-aminobutyric acid-A
(GABAa) receptors as a cause of atypical/classic RTT phenotype, in accordance with the deregulation
of GABAergic pathway observed in MECP2 defective in vitro and in vivo models.
Int. J. Mol. Sci. 2019, 20, 3621; doi:10.3390/ijms20153621 www.mdpi.com/journal/ijms
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1. Introduction
Rett syndrome (RTT) is a neurodevelopmental disorder, with an incidence of approximately
1 in 10,000 live births, most frequently affecting girls during early childhood [1]. RTT patients
develop normally during the first 6–18 months of life, but over time they manifest a motor and
psychomotor regression and gradually develop a severe condition associated with motor, cognitive
and behavioral impairment. Up to 95% of classical RTT cases are accounted for by mutations in the
Methyl CpG-binding protein 2 gene (MECP2) [2], mapping at Xq28 and encoding a multifunctional
protein whose expression impacts many fundamental biological processes [3]. The MeCP2 protein
acts as epigenetic “reader” [4] which by binding with methylated DNA, interacting with corepressors
and recruiting histone deacetylases to methylated genes, leads to their silencing [5], but it can also
dampen transcriptional noise genome-wide, altering global chromatine structure [6]. MeCP2 is
also a transcriptional activator through its interaction with the c-AMP responsive element-binding
protein 1 (CREB1), has a role in alternative splicing in a DNA methylation-dependent manner and in
microRNA processing and may influence global translation through modulation of the AKT/mTOR
pathway [7–9]. In RTT patients, the differential expression of multiple genes related to intracellular
signaling, modulation of cytoskeleton plasticity and cell metabolism [9] support the involvement
of MeCP2 in neural development and synaptic function. Interestingly, perturbations in the genes
acting in GABAergic circuits [10] could result in neuron hyperexcitability, which in turn is potentially
responsible for epilepsy reported in 60–80% of RTT patients [11].
Similar to the classical form, atypical or variant RTT present many RTT clinical features, but do not
necessarily meet all the distinctive signs of the disorder; however highly stringent criteria allow proper
definition of the variant forms [12]. A fraction ranging from 5% to 8% of classic RTT [2,13] and 42% to
73% of variant RTT patients [13,14] are negative for MECP2 mutation. Among them, individuals with
early seizure onset variant RTT [15,16], who manifest epilepsy before regression, have mutations in the
cyclin-dependent kinase-like 5 gene (CDKL5), and patients with congenital RTT, who show gross early
abnormal development, have molecular defects in the forkhead box G1 gene FOXG1 [17]. However,
a subset of patients who receive the clinical diagnosis of RTT remain negative for mutation in all the
aforementioned genes. Next generation sequencing (NGS) and particularly Whole Exome Sequencing
(WES) have emerged as a powerful tool to identify new genes involved in rare genetic diseases [18] and
to give a diagnosis to patients without a known genetic cause. Thanks to these technological advances,
in the last few years, several uncommon causative genes for classic or variant Rett syndrome or similar
phenotypes (RTT-like) have been discovered [11,14,19–24]. Among the novel genes, several have been
previously associated with developmental delay, often in comorbidity with epilepsy. An emerging
concept is that some genes causing epileptic encephalopathy may be responsible for more complex
neurodevelopmental disorders (DEE, Developmental and Epileptic Encephalopathies), where both ID
and epilepsy contribute to the clinical phenotype [25–27].
Based on these premises, we expected that a proportion of patients with RTT phenotype and
epilepsy might be mutated in one of the genes involved in DEE.
In order to identify new genes responsible for the RTT phenotype, we processed by WES 26 girls
with a RTT/RTT-like phenotype negative to the conventional genetic test for RTT and by NGS Custom
multigene Panel a cohort of 78 patients with pediatric age onset seizures, that included 11 patients
with RTT/RTT-like phenotype.
The combined approaches allowed the identification of a genetic cause different from customarily
studied genes in RTT syndrome in six patients. Following this result, processing 100 patients with
RTT/RTT-like syndrome or syndromes in differential diagnosis by using an NGS custom panel enriched
in the new genes allowed the detection of two additional cases. Lastly, all the molecularly defined
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patients were clinically re-evaluated to highlight the occurrence of distinctive phenotypic traits that
might specifically guide the molecular investigation of the genes identified in this study.
2. Results
Overall, the NGS experiments identified eight patients carrying a pathogenic variant in genes
alternative to the customarily tested genes in RTT syndrome. Table 1 summarizes the patients’ clinical
features, the pathogenic variant and the NGS approach. The clinical features have been grouped
according to Neul classification [12] under separated entries distinguishing main and supportive
criteria. Epilepsy characteristics and neurological disturbances not specifically related to RTT are
reported in Table S1. All patients showed epilepsy during their lifetime. Six patients (No. 1–6) exhibited
a pathogenic variant in the STXBP1 gene (OMIM 602926), one patient (No. 7) showed a pathogenic
variant in GABRG2 (OMIM 137164), while another one (No. 8) had a pathogenic variant in GABRB2
(OMIM 600232).
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Table 1. Patient’s clinical features grouped according to Neul classification, the pathogenic variants and the Next generation sequencing (NGS) approach.
Patient 1 2 3 4 5 6 7 8
Sex, Current Age (years) F (18 y) F (11 y) F (19 y) F (29 y) F (7y) F (9 y) F (38 y) F (42 y)
Molecular Approach NGS-pediatric epilepsy WES-RTT WES-RTT NGS -pediatric epilepsy NGS-diagnostic NGS-diagnostic NGS -pediatric epilepsy WES-RTT
Mutation/Inheritance Pattern
STXBP1 NC_000009.11:
g.130423471 C>T,
NM_003165.3:
c.416C>T:
p.(Pro139Leu), de novo
STXBP1 NC_000009.11:
g.130435529 C>T,
NM_003165.3:
c.1099C>T:
p.(Arg367Ter), de novo
STXBP1 NC_000009.11:
g.130416077 T>C,
(NM_003165.3):
c.169+2T>C,
r.([169_170 ins
[gc;169+3_169+1168];
169_170ins [gc;
169+3_169+1334]]),
p.(Ile57Serfs7*) de novo
STXBP1 NC_000009.11:
g.130428548 T>C,
NM_003165.3:
c.767T>C,
p.(Leu256Pro), de novo
STXBP1 NC_000009.11:
g.130444840 G>A,
(NM_003165.3)
c.1702+1G>A, r.
[1585_1702del117]
p.(Glu530_Gly 568del)
de novo
STXBP1 NC_000009.11:
g.130438188 C>T,
NM_003165.3: c.1216
C>T, p.(Arg406Cys),
de novo
GABRG2 NC_000005.9:
g.161576128_161576129
delinsGG,
NM_000816.3:
c.937_938 delinsGG,
p.(Leu313Gly),
de novo mosaic
GABRB2 NC_000005.9:
g.160758063 C>T,
NM_021911.2:
c.904G>A
p.(Val302Met), de novo
Regression (age indicated) Followed
by Recovery or Stabilization No cdv No cdv No cdv No cdv No Yes (6 months) Yes (12 months) Yes (9 months)
M
ai
n
C
ri
te
ri
a
Partial or Complete
Loss of Acquired
Purposeful Hand Skills
No: not lost, but
NevAcq (grabs food
and takes it to her
mouth)
No: not lost, but
NevAcq (grasping and
manipulation disturbed
by involuntary
movements)
No: not lost, but
NevAcq (grasping
disturbed by tremors
and stereotypies)
No No: very limited handskills
No: not lost, but Nev
completely Acq
Yes: very limited hand
skills
Yes: (since 2 years
leaves behind and
drops things)
Partial or Complete loss
of Acquired Spoken
Language
No: not lost, but
NevAcq
No: not lost, vocalisms
and only ten words
No: not lost, but
NevAcq
No: not lost, only a few
words
No: not lost, but Nev
Acq, only vocalisms
No: not lost, but
NevAcq(vocalism)
No: not lost, but
NevAcq
Yes (only “Mum” and
“Dad”, then lost)
Gait Abnormalities:
Impaired or Absence of
Ability
Yes (ataxic-dyspraxic,
unstable and only for
short distances: since
4 years)
Yes (ataxic with axillary
support: since 4 years)
Yes absent (only
standing with
axillary support)
Yes ataxic (walking
with enlarged base and
out of rotation of feet:
since 3 years)
Yes (walking with
enlarged base/ not
apraxic: since 3 years)
Yes (Nev Acq) Yes (ataxic: since6 years)
Yes (apraxic, slow but
autonomous, since
16 months, climbs the
stairs)
Stereotypic Hand
Movements (type)
Yes frequent (brings her
hands to mouth and
bites fingers)
Yes (not typical for RTT,
beats her head: since
3 years)
Yes (hand washing) Yes (hand rocking)
Yes (hand washing,
clapping, tapping right
hand on table/books,
tapping the forehead
with the right upper
limb, upper limb
flickering)
Yes (upper limbs
tremors, upper limb
flickering, and
dyskinesias)
Yes (tapping her right
hand on her teeth:
since 18 months),
Yes (upper limbs
flickering)
Ex
cl
us
io
n
C
ri
te
ri
a
Brain Injury: Peri or
Postnatal Trauma,
Neurometabolic
Disease or Severe
Infection
No No No No No No No No
Grossly Abnormal
Psychomotor
Development in First 6
Months of Life: Exam
at the Birth
hypotonia normal normal
hypotonia,
hyperexcitability,
inconsolable crying
normal normal normal normal
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Table 1. Cont.
Patient 1 2 3 4 5 6 7 8
Su
pp
or
ti
ve
C
ri
te
ri
a
Breathing Disturbances No Yes No No No No Yes (mild cyanosis andapneas) Yes (hyperventilation)
Bruxism when Awake No No Yes No Yes Yes Yes Yes (significant)
Impaired Sleep Pattern Yes (sleeplessness andnocturnal agitation) Yes (seizures) Yes (nocturnal bruxism) No
Yes (several and
prolonged nocturnal
awakenings)
No Yes No
Abnormal Muscle Tone Yes (proximalhypotonia) Yes Yes No No
Yes (axial hypotonia,
hypertonus of the
limbs)
Yes mild hypertonus
(hypotonia in the first
years of life)
No
Peripheral Vasomotor
Disturbances No No Yes No No No
cold and bluish hands
and feet without
trophic changes
No
Scoliosis/Kyphosis Yes (lumbarhyperlordosis) Yes (mild) Yes No No No Yes (mild kyphosis)
No (only scoliotic
attitude)
Growth Retardation No No No hypostaturism andobesity No Yes Yes mild No
Small Cold Hands/Feet Yes No Yes No (but short andstubby fingers) No Yes (small, not cold) Yes Yes (cold feet)
Inappropriate
Laughing /Screaming
Spells
Yes No Yes (screams) No Yes nd Yes frequent Yes rare
Diminished Response
to Pain Yes No No nd Yes nd nd No
Intense Eye
Communication No Yes No No Yes No Yes Yes
Microcephaly: if Yes Indicate if
Acquired Yes acquired No No No No Yes acquired No Yes acquired
Clinical Diagnosis at Referral RTT atypical RTT atypical Hanefeld RTT atypical congenital RTT-like-EOEE(West>Lennox-Gastaut) RTT atypical
RTT-like (myoclonic
epileptic
encephalopathy)
RTT atypical RTT classic
WES-RTT= Whole Exome Sequencing on Rett Syndrome; RTT = Rett Syndrome; NGS = Next generation Sequencing; WES = Whole Exome sequencing; cdv = Congenital Developmental
Delay; nd = not done; Nev Acq = Never Acquired.
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2.1. STXBP1 Variants
Two out of the six variants in STXBP1 (patients No. 3 and 4) had never been described in the
literature and the two splicing variants of patients No. 3 and 5 had never been studied at transcript level.
Therefore, in order to corroborate the pathogenicity of these latter variants, we characterized
the transcripts obtained by peripheral blood. To evaluate the effect of the mutation NC_000009.11:
g.130416077 T>C, (NM_003165.3): c.169+2 T>C of patient 3 (Figure 1) we set up two distinct
PCRs on STXBP1 cDNA: one with a reverse primer including the splice junction and a part of
the two flanking exons 4 and 5 and the forward in exon 2, and another with a forward primer
complementary to the intronic sequence, to check for possible splicing retention phenomena, as
described for a different mutation hitting the same splice site [28]. The second primer set allowed
us to highlight that the variant gives rise to two aberrant transcripts, a-Tr1 and a-Tr2, retaining part
of IVS3 (r.([169_170ins[gc;169+3_169+1168];169_170ins[gc;169+3_169+1334]])). For both transcripts
the predicted outcome is a protein prematurely truncated 57 aminoacids after the end of exon 3
(p. (Ile57Serfs7*)) and completely missing the functional domains of the Syntaxin–binding Protein 1.
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In patient 5, the splice variant NC_000009.11: g.130444840 G>A, (NM003165.3) c.1702+ 1G>A in 
STXBP1 gene generates an aberrant transcript due to the choice of a new donor site within exon 18 
stronger than the aberrant one, with deletion of the last 117bp of this exon (r.[1585_1702del117]) 
Figure 1. (A) Schematic representation of STXBP1 gene primer pairs used for characterization of patient
3 variant and on the right the electropherogram with the heterozygous variant. (B) The 2% agarose gel
shows the wt amplicon of 190 bp in the first PCR (ex2F/ex4–5R) (blue arrow) and a weak signal of two
aberrant fragments only in the proband (P). Two long amplicons obtained by a primer pair selective for
the aberrant transcript (Ex3-int3-mutF/ex4–5R) are well visible in the proband’s lanes (P) (red arrows)
and not in the control DNA lane (C). (C) Schematic of the mis-splicing caused by the c.169 + 2T> C
mutation inferred by sequencing of the two amplicons that correspond to two aberrant intron-retaining
transcripts resulting from the use of two alternative donor sites (in red) 1168 and 1134 nt downstream
from the end of exon 3.
In patient 5, the splice variant NC_000009.11: g.130444840 G>A, (NM003165.3) c.1702+ 1G>A
in STXBP1 gene generates an aberrant transcript du to the choice of a n w donor site within exon
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18 stronger than the aberrant one, with deletion of the last 117 bp of this exon (r.[1585_1702del117])
predicting a protein, with an in frame deletion of 38 amino acids (p.(Glu530_Gly568del)), devoid of
a large portion of the functional D2 domain (Figure 2).
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Figure 2. (A) Schematic representation of the wild type (wt-Tr) and the aberrant transcript (a-Tr1)
generated by variant NC_000009.11: g.130444840 G>A, (NM003165.3), c.1702 + 1G>A of patient 5,
resulting in the deletion of the last 117 bp f exon 18. (B) cDNA electropherogram showing the wt
transcript (black and green letters) and the aberrant transcript (black and purple letters) produced
through the choice f a new donor site within exon 18 at position c.1585 (arrowed).
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2.2. Clinical Features of Girls with STXBP1 Variants
Table 1 and Table S1 detail the phenotypic traits of the patients with STXBP1mutation. In summary,
the clinical re-examination took into account the RTT criteria revisited by Neul [12], the epileptic
profile and the phenotypic traits usually observed in STXBP1-mutated patients, such as movement
disorders. Although the patients had been referred to the molecular study as atypical RTT (early
seizures onset RTT or congenital) or RTT-like (see Table 1 “Clinical Diagnosis” at referral) and all
presented hand stereotypies (which in 2 patients are typical for RTT such as “hand washing”), absence
or walking/gait abnormalities and absence of purposeful hands skills and language, only patient 6 had
a true regression, distinguishing them from RTT. The occurrence of supportive criteria for RTT varies
from patient to patient, apart from hypotonia which recurs in four out of six patients. Movements
disorders, typical of STXBP1-mutated patients are frequent (tremors and dyskinesia in 5/6 patients).
Epilepsy was referred in all of the six girls but: a) the age of seizures onset was very variable, occurring
later than expected for STXBP1-EE (on average at six weeks) [25] in three out of six patients; b) the type
of crisis was heterogeneous and only in one patient (No. 4) the onset was typical for West syndrome;
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c) the pharmacological response varied from drug resistance to responsiveness. Only patient 4 showed
the typical hypsarythmic pattern associated with West syndrome.
2.3. GABAa Receptors Genes Variants
The patient No. 7 carried a pathogenic variant inGABRG2never described in literature. The variant
is a double nucleotide substitution in the first and second nucleotides of the CTG codon (Leu) in
position 313 of the GABRG2 gene (Figure 3). The analysis by True Seq Custom Amplicon (see File
S1) on genomic DNA from peripheral blood showed that the two substitutions are in cis and create
the novel GGG codon (Gly) (according to HGVD nomenclature guidelines the deletion/insertion
format is preferred, therefore variant is NC_000005.9: g.161576128_161576128 delinsGG, NM_000816.3:
c.937_938delinsGG, p.(Leu313Gly)). NGS approach showed a read count for the variant equal to about
12% of the total (Figure 3B), barely detectable even with Sanger Sequencing (Figure 3A). The analysis
on buccal swab DNA by Nextera approach using three different pairs of primers (see File S2), showed
a percentage similar to that observed in blood (Figure 3C), excluding the occurrence of a partial allelic
drop-out and supporting a real mosaicism condition. This variant is predicted as pathogenetic by the
Alamut software. Parents’ analysis on genomic DNA from both blood and buccal swab carried out by
Sanger and Nextera sequencing proved the de novo origin of the mutation.
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p.(Val302Met) of patient 8, although unreported in literature, is present in ClinVar as probably 
pathogenetic and is localized in the same region (the extracytoplasmic loop between the TM2 and 
TM3 chains) of the mutational hot spots p.Lys303Arg and p.Lys303Asn [26,29] and close to the 
Figure 3. (A) Patient electropherograms show the mosaic double nucleotide substitution in the first
and second position of the CTG codon (framed) with the mutated GGG codon (framed) replacing
the aminoacid Leu at position 313 of the GABRG2 gene with Gly. (B) Annovar table revealing
the low-rate (12%) mosaicism for the double base substitution in DNA from peripheral blood.
(C) Nextera-XT-Library-prep protocol performed with three different pairs of primers (red-blue-green)
shows on DNA from buccal swab a mosaic mutation percentage comparable to that obtained on blood.
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The de novo variant in GABRB2, NC_000005.9: g.160758063 T>C, NM_021911.2: c.904G>A
p.(Val302Met) of patient 8, although unreported in literature, is present in ClinVar as probably
pathogenetic and is localized in the same region (the extracytoplasmic loop between the TM2 and TM3
chains) of the mutational hot spots p.Lys303Arg and p.Lys303Asn [26,29] and close to the p.Ala304Val
mutation [26,30].The pathogenicity is indicated by the in silico predictions using Alamut software
(Figure S2).
2.4. Clinical Features of Girls with Variants in GABAa Receptors Genes
According to the Neul criteria [12], the two patients with pathogenic variants in GABAa Receptors
genes can be classified as RTT, since they presented a true regression, patient 7 as atypical RTT (3
primary criteria and> 5 supportive criteria) and patient 8 as classical RTT (4 primary criteria). In two
patients epilepsy is not triggered by fever and in patient No. 8 the age of onset of seizures was not
very early.
3. Discussion
The widespread use of NGS targeted to multi-gene panels or to the whole exome has shown
that a notable number of patients referred with a suspected syndromic diagnosis turned out to be
carriers of a pathogenic variant in genes not classically associated with the initial clinical diagnosis.
The molecular definition of syndromes affecting the neurodevelopment associated with epilepsy
remains a challenge, often hampered by the genetic heterogeneity [31]. In any case, a clinical diagnosis
based on stringent diagnostic criteria commonly recognized by the scientific community should remain
an initial milestone. Furthermore, the clinical diagnosis of Rett syndrome (RTT OMIM 3127520) is
advantaged by the definition of stringent clinical criteria, which upon revision [12] allow classification
and distinguishing classical RTT from both early onset epilepsy and congenital atypical RTT, the latter
two mainly ascribed to disease causing variants in the CDKL5 and FOXG1 genes. On the other hand,
when molecular tests exclude the involvement of the three canonical genes, the most frequent choice
is a wider investigation usually starting with NGS targeted to multi gene panels including those
associated with epilepsy and neurological disorders and often ending with the more expensive and
time-consuming WES. According to recent literature [11,14], more than 69 genes from these studies
turned out to be candidate genes for RTT/RTT-like phenotypes.
The availability of a large cohort of girls referred to our lab with suspected RTT and found negative
for the canonical RTT genes, prompted us to perform NGS targeted to gene panels and/or the whole
exome, a common strategy which succeeded in identifying so far in our cohort pathogenic variants in
the STXBP1 gene and in two different subunits of GABAa receptor in six and two girls, respectively.
In keeping with the role of these genes, all eight patients experienced early-onset seizures (from the
neonatal period to the second year of age). In order to pinpoint the existence of distinctive phenotypic
traits helpful in addressing the molecular investigation of these three genes and designing a proper
therapy, the clinical history and features of all eight girls were reviewed by their child neurologists and
clinical geneticists and compared to the RTT diagnosis criteria.
STXBP1 encodes the presynaptic protein Munc18-1, a protein binding and stabilizing the complex
of SNARE (Soluble NSF Attachment Protein REceptor) proteins, actively involved in the fusion between
synaptic vesicles and the presynaptic membrane, thus favoring neuronal exocytosis [32]. Functional
in vitro studies and experiments on Stxbp1 mouse models [33] demonstrated that instability of defective
Munc18-1 protein and the consequent haploinsufficiency may explain the mechanism underlying
the STXBP1 encephalopathy (EIEE4, OMIM 612164). GABAergic more than glutamatergic neurons
seem impaired, probably resulting in an imbalanced excitability in the neocortex, responsible for
an abnormal epileptic activity [34,35]. The phenotype of patients with a STXBP1 pathogenic variant
ranges [25] from the generic early onset epilepsy encephalopathy, to Ohathara syndrome [36,37],
EME [38], West syndrome [39,40], Dravet syndrome [41], but also includes intellectual disability (ID)
in the absence of epilepsy [42–44], classic MECP2-negative RTT and atypical RTT [45]. As the degree of
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ID does not appear to correlate with the severity of the seizures and/or the age of onset of epilepsy,
STXBP1-EE is not thought to be a simple Early Onset Epileptic Encephalopaty-EOEE, but a more
complex neurodevelopmental disorder (DEE, Developmental and Epileptic Encephalopaty), where
both ID (often occurring before the onset of epilepsy) and epilepsy play a synergic role in the phenotype
evolution [25–27]. Considering that only four STXBP1 positive girls, two with a classical RTT [46,47],
one with atypical RTT [48] and one male with RTT-like phenotype [21] had been reported, the patients
described herein increase the overall number of RTT/RTT-like patients caused by pathogenic variants
in STXBP1. Variants in patients No. 3 and 4 have never been reported in literature, while concerning
the remaining mutations [25,49,50], one (p.(Pro139Leu)) is a mutational hotspot [51–53].
A review of clinical history of our patients and a comparison with the described cases highlighted
the fact that all our STXBP1 girls share hand stereotypies and abnormal, impaired ataxic or absent gait
and do not have purposeful use of hands and language, which has never, or in a very limited way, been
acquired and has not been lost. Furthermore, only patient 6 presented a regression. Since the presence
of regression is a fundamental criterion for the diagnosis of RTT syndrome, according to the Neul
criteria, our cases should not be classified as RTT, but RTT-like. However, MECP2-positive patients
presenting abnormal signs or deviant developmental profiles before 6 months who subsequently
acquired supportive criteria have been reported [54,55] (defined as atypical congenital RTT) and an
eventual regression before 6 months of age is difficult to identify also because ”typically the family
and the primary clinician is not concerned about development until after 6 months of age” [12,56],
suggesting that at the least our STXBP1 patients 1, 2, 3 and 5, who show two main criteria and
>5 supportive criteria might be included in the subset of atypical/congenital RTT variants. Moving
to the epileptic phenotype, the West syndrome history experienced by three of the four reported
RTT patients with STXBP1 variants [21,46–48], was not observed in our cases, with the exception of
patient 4.
Furthermore, our STXBP1 patients did not resemble the RTT Hanefeld variant due to mutations
in CDKL5 gene and characterized by a typical course of epilepsy [57], nor did they seem to share
a common epilepsy history and the age of seizure onset appeared to be quite different. Drug resistance,
common in RTT Hanefeld variant patients [58] was present only in one out of our six cases. Moderate
to severe ID is evident in all six patients, bruxism during wakefulness is present in three out of
six girls, a characteristic shared with RTT and STXBP1-DEE patients [59]. The small number of
reported cases with STXBP1 mutations and RTT/RTT-like diagnosis does not allow the definition of
a correlation between mutation type and severity of the phenotype or epileptic profile. On the other
hand, studies on a wide cohort of STXBP1-positive patients did not reveal any genotype–phenotype
correlation [25]. In conclusion, the identification of six patients with a pathogenic defect in this gene
from a RTT/RTT-like cohort of 137 patients (4.4%) suggests the performing of STXBP1 analysis when
a congenital phenotype, characterized by the main criteria for RTT syndrome and associated with
epilepsy is observed. Seizures may appear after developmental delay and are not necessarily drug
resistant or associated with West phenotype.
We also identified a patient with a mutation in GABRG2 which encodes the gamma subunit of the
heteropentameric GABA type A (GABAa) receptor in the form α2β27. It represents the most abundant
inhibitory receptor subtype in the CNS [60], and the primary mediator of fast inhibitory synaptic
transmission. The gamma subunit oligomerizes in the endoplasmic reticulum (ER) with the other
subunits and is required for postsynaptic GABAa receptor clustering [61,62]. To date, only about twenty
mutations associated with different epileptic phenotypes have been described, from mild (FS, Febrile
Seizures or CAE, Childhood Absence Epilepsy) to moderate (GEFS +, Generalized Epilepsy with Febrile
Seizures +), to severe [61] Dravet syndrome (DS) [63], or early onset encephalopathy phenotype [64,65],
but never underlying the RTT phenotype. Clinical heterogeneity may depend primarily on how the
mutation interferes with the assembly of the mutant with the other subunits, causing mechanisms of
haploinsufficiency or dominant negative suppression [61]. A genotype-phenotype correlation study
had previously associated missense mutations with milder clinical phenotypes and truncating variants
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with more severe phenotypes [61], but recent reports [63,64] identified several missense mutations in
epileptic encephalopathy and DS as well. The mosaic p.(Leu313Gly) variant of patient 7 (see Figure 3),
never described in literature, changes a highly conserved residue in the TM2 also located in the
pore-lining region likewise the p.(Pro302Leu) mutation, which is associated with the severe phenotype
of DS and that determine a dramatic whole-cell current reduction, resulting in hyperexcitability [63].
Moreover, a decrease in maximal response to GABA was observed for mutations located in TM2 [64].
The key location of the mutation together with the in silico predictions support its pathogenicity with
regard to the epileptic phenotype, highlighting a new genotype-phenotype correlation according to
which missense mutations associated with severe phenotype are located in the pore forming region of
the channel, while the missense mutations affecting the N-ter or the extracytoplasmatic loop region
underlie a mild phenotype. However, the condition of the mosaic mutation (described for this gene in
Stosser 2018 [66] in an epileptic male scarcely defined in the phenotype, with a mutation percentage
similar to that of our patient, but with localization in the N-terminal region) could be compatible with
a milder phenotype, at least for the epileptic features. Although the condition of disability appears
severe in our patient, she is now seizure-free. More generally, the evidence of mosaic status, at the
limits of Sanger sequencing sensitivity, suggests the opportunity to retest negative patients by the more
sensitive NGS approach, mainly for genes involved in epilepsy where mosaic mutations seem to be
frequent [66–68].
Lastly, patient 8 carries the de novo unreported mutation in the GABRB2 gene, p.Val302Met.
GABRB2 encodes the beta subunit of the GABAa ionotropic heteropentameric receptor, which also
includes the 7 subunit encoded by GABRG2, with which it shares the structure, common to all
the GABAa receptors subunits [69]. To date, only 13 mutations have been described in this gene,
clustered mainly in the 3 TM1–TM3 transmembrane domains and in the linker regions between
them, responsible for IECEE2 (Infantile or Early Childhood Epilepsy Encephalopaty type 2, OMIM
617829), a neurodevelopmental disorder characterized by the onset of epilepsy in infancy or childhood,
developmental delay and variable ID [26,30,70,71]. To our knowledge, only one other patient, carrying
the p.Ala304Val mutation which is very close to the residue mutated in our patient, has a phenotype
classified as atypical RTT [30].
According to Neul’s criteria, patients 7 and 8 can be classified RTT, since they exhibited regression,
unlike those mutated in STXBP1. In the reported GABRG2 patients, the onset of seizures, beyond
the severity of the clinical picture, is often triggered by fever, data not registered in patients 7 and 8.
With regards to GABRB2, epilepsy is present in almost all the patients so far described, but the age
of onset in patient 8 is later (2 years) (Table S1) than that (within the first year of life) reported [26].
Although replication of these findings in more patients is needed for a correct genotype-phenotype
correlation and to establish differences and similarities with RTT patients mutated in classic associated
genes, our data suggests testing this gene in negative RTT cases that meet Neul criteria for classic and
atypical forms with epilepsy presenting not necessarily at very early onset.
The identification of mutated patients inGABRB2 andGABRG2 is in agreement with the observation
of deregulation of the GABAergic pathway in murineMecp2-deficient models [72,73] and iPSCs-derived
neurons of MECP2 mutated patients [10]. The evidence that haploinsufficiency of STXBP1 also affects
more inhibitory GABAergic than glutamatergic neurons [35] supports the hypothesis that the alteration
of the GABAergic pathway is of primary importance in the RTT phenotype and the genes acting in this
pathway may represent a target for mutational screening in RTT/RTT-like patients, as well as a key
gene network in the future treatment of the disorder.
4. Materials and Methods
4.1. Patients
Twenty-six girls (aged from 5 to 38 years), accurately selected by a number of different Italian
neuropsychiatric departments, classified as follows: 14 as Classical Rett, five as Atypical Early Onset,
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five as congenital Rett and two females as Rett-like, according to Neul classification, were tested in
2013 by a WES experiment.
Seventy-eight patients (72 singleton plus 3 pairs of siblings, of which 49 females and 29 males,
aged from 1 to 49 years) characterized by a) neonatal, infantile or childhood onset seizures, and/or or b)
drug resistant epilepsy and/or c) progressive worsening of the clinical course associated with epilepsy
and/or d) autistic traits and/or e) intellectual disability, were tested by NGS Custom Panel for pediatric
epilepsy; 11 of them were classified by clinicians as RTT/RTT-like.
One hundred patients referred to our lab with clinical suspicion of RTT/RTT-like, were screened
by NGS Custom panel in use in IAI laboratory since 2016 for diagnostics of RTT and syndromes in
differential diagnosis.
All positive patients were referred to our laboratory by a number of Italian neuropsychiatric
departments.
A written consent was signed for all patients by their families. The study was approved by IRCCS
Istituto Auxologico Italiano Ethical Committee on 03/04/2012 (protocol number 2012_04_03_05-Project
MOH 08C208 and AIRETT) and on 12/03/2013 (protocol number 2013_03_12_14-Project MOH 08C305).
4.2. Methods
Genomic DNA was extracted from peripheral blood leukocytes using Freedom Evo
TECAN extractor.
4.2.1. WES
The WES experiment was performed on Illumina Hi Scan SQ platform and technology (Illumina,
San Diego, CA, USA); the True Seq Exome Enrichment Kit enables the enrichment of the coding portion
as well as the adjacent intronic and 5’-3’-untranslated regions.
Sequencing Data Analysis
The text files of exome sequences were aligned to the Human assembly GRCh37/h19, using the
Burrows-Wheeler alignment tool, BWA [74] to generate Binary Alignment Map (BAM files). Variant
calling was performed using the Genome Analysis Tool Kit (GATK) [75] and Genotyping identification
was performed using GATK’s Unified Genotyper [76]. Variants were subsequently annotated for their
existence in dbSNP, also harboring all properties described in dbSNP for known variants (e.g., GMAF).
The possible impact of variations was evaluated using SnpEff [77]. Additional bioinformatics tools
were applied (SIFT score, Polyphen prediction, GERP score) using the NSFP database [78], to assess
their potential noxious effect.
The coverage at each nucleotide was extracted from each subject’s exome BAM file. The average
exome sequence coverage per individual was 40 X ranging from 20 X to 67 X at the target exome sequence.
Selection of Potentially Causative Variants
We utilized a custom-built interpretation scheme to identify possible causative variations, based
on several parameters including minor allele frequency, conservation, mutation type, predicted
pathogenicity, presence (in public databases or in literature) in genes already known to be associated
with phenotypes sharing common aspects with RTT or in genes involved in pathway relevant to the
development and features of the central nervous system. The prioritization was carried out using specific
bioinformatic tools as ToppGene (toppgene.cchmc.org) [79] and DAVIDgene (david.abcc.ncifcrf.gov).
Before proceeding to Single Nucleotide Variation (SNV) validation by Sanger Sequencing, prioritized
genes were further investigated individually by literature updates (www.ncbi.nlm.nih.gov/pubmed)
and through a range of bioinformatic websites providing further information about locus-specific
databases, protein structure, function, expression and interacting networks (www.genome.jp/kegg/,
ncbi.nlm.nih.gov/gene, www.genecards.org/).
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4.2.2. NGS Custom Panel for Pediatric Epilepsy
A Custom Illumina Panel covering coding regions and their intron–exon boundaries (flanking
20 nucleotides) of 33 genes (see Supplementary File S3) causing neonatal, infantile or childhood onset
seizures and/or autism was created in 2014 for sequencing using the True Seq Custom Amplicon
protocol according to the reference guide and analyzed in-house on an Illumina MiSeq instrument
(Illumina, San Diego, CA, USA).
4.2.3. NGS Custom Panel for Diagnostic Analysis
Genomic sequencing of whole coding region and intron-exon junctions of 35 genes involved in
RTT and syndromes in differential diagnosis (see Supplementary File S3) was performed by Illumina
Nextera Rapid Capture Enrichment protocol, following the manufacturer’s instructions.
For both approaches of NGS Custom Panel, the genomic regions with a coverage of less than 20 X
were analyzed by Sanger Sequencing or Nextera-XT-Library-prep protocol (Illumina) using MiSeq
Instrument for sequencing.
4.2.4. Variants Validation
The variants identified by all three experiments were validated by Sanger Sequencing using
a Big-Dye® Terminator v3.1 Cycle Sequencing Kit and analyzed in an Applied Biosystems Abi Prism
3500 Sequencer. The primers used for Sanger sequencing are shown in Table S2. Sanger sequencing
was also performed on DNA from patients’ parents. We analyzed microsatellite parental inheritance in
order to confirm the correct family relationship and avoid any possible sampling error. Microsatellite
analysis was performed using the commercial kit ChromoQuant® QF-PCR (CyberGene AB, Solna,
Sweden) which evaluates polymorphic loci on chromosomes X, Y, 13, 18 and 21, according to the
manufacturer’s protocol and analyzed on an ABI Prism 3500 sequencer (Applied Biosystems, Foster
City, CA, USA).
For STXBP1, splicing variants total RNA was extracted from peripheral blood leukocytes using
Tempus Spin RNA Isolation Kit (Applied Biosystems-Termofisher, Waltham, NA, USA) and reverse
transcribed to cDNA by SuperScript VILO Kit (Invitrogen-Termofisher, Waltham, NA, USA). cDNA
was amplified by Go Taq Hot Start Polymerase (Promega, Madison, WI, USA) and sequenced using
the Big DyeTerminator v.3.1 Cycle Sequencing Kit (Applied Biosystems) with primers: STXBP1ex2F
5’AAGAAGAAGGGGGAATGGAA3’, ex4-5R 5’GAGAGTGGACGGACTTCTCG3’ and Ex3-int3-mutF
5’AGGCATAACGAgcgagca, STXBP1 ex15-16F 5’ACCGATTCCACGCTGCGTCG3’, STXBP1ex19R
5’CCATTGTTGGAGCCTGATCC3’ and run on ABI PRISM 3500 sequencer (Applied Biosystems).
In the case of patient No. 7, Sanger Sequencing and Nextera-XT_library-prep protocol
was also conducted on DNA extracted from buccal swab collected with Oragene-DNA OG575,
using prepIT L2P kit (DNA genotek, Ottawa, Canada). Three different pairs of primers
were used to validate the variant on saliva and blood in the patient and her parents:
GABRG2EX8TrueSEQredF 5’AGTCTCACGAGTGACTCAGTTACCCAA3’, 5’GABRG2EX8True
SEQredR GTTATGGCCTGGCTAAACTCATACATG3’, GABRG2EX8blueF 5’tccctgtattctccatggca3’,
GABRG2EX8blueR 5’TTGTCCTTGCTTGGTTTCCG3’, GABRG2EX8greenF 5’ttcccattgctgaaactgcc3’,
GABRG2EX8greenR 5’CCTTGCTTGGTTTCCG3’.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/20/15/
3621/s1.
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Abbreviations
RTT Rett Syndrome
MECP2 Methyl CpG-binding protein 2
CREB1 cAMP Responsive Element Binding Protein 1
mTOR Mammalian Target of Rapamycin
GABA Gamma-aminobutyric acid
CDKL5 Cyclin-dependent kinase-like 5
FOXG1 Forkhead box G1 gene
NGS Next generation sequencing
WES Whole Exome Sequencing
DEE Developmental and Epileptic Encephalopaty
ID Intellectual Disability
EE Epileptic Encephalopaty
EOEE Early Onset Epileptic Encephalopaty
EIEE Early Infantil Epileptic Encephalopaty
STXBP1 Syntaxin-binding protein 1
GABRB2 Gamma-aminobutyric acid type A receptor beta2
GABRG2 Gamma-aminobutyric acid type A receptor gamma2
EME Early Myoclonic Encephalopathy
SNARE Soluble NSF Attachment Protein REceptor
Munc18-1 Mammalian uncoordinated-18-1
CNS Central Nervous System
FS Febrile Seizures
CAE Childhood Absence Epilepsy
GEFS + Generalized Epilepsy with Febrile Seizures plus
DS Dravet syndrome
TM Transmembrane Domain
ER Endoplasmic Reticulum
IECEE2 Infantile or Early Childhood Epilepsy Encephalopaty type 2
NTS Nucleus of the solitary tract
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